Karachi: Macter International Limited announced the successful launch of Semaglutide in Pre-Filled Syringe (PFS) and Pre-Filled Multi-Dose Pen (PFP) presentations on November 7, 2025. This development is in accordance with Section 96 and 131 of the Securities Act, 2015, and Clause 5.6.1 of the Rule Book of Pakistan Stock Exchange Limited.

Semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, is extensively used for managing Type 2 Diabetes Mellitus. The pharmaceutical is also gaining recognition for its role in weight management and metabolic health. With this launch, Macter International Limited becomes the exclusive provider in Pakistan to offer Semaglutide in all three biotechnology dosage formats, which include Vials, Pre-Filled Syringes, and Pre-Filled Pens.

According to information available from the Pakistan Stock Exchange (PSX), this milestone underscores Macter's commitment to expanding its Biotech portfolio. The launch is considered a significant advancement in providing advanced and globally competitive therapies to patients in Pakistan. This effort reinforces the company's leadership position in the pharmaceutical market, particularly within the designated market category of biotechnology and pharmaceuticals.

The introduction of these new dosage formats is poised to enhance treatment options for patients, aligning with Macter's strategic objectives to innovate and address the increasing health needs of the local population.